Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 747.5	$ 969.2
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	512.0	149.7
Share-based compensation	37.0	45.3
Deferred income taxes	76.1	8.9
Other	18.1	(11.9)
Changes in operating assets and liabilities, net:
Accounts receivable	(195.7)	(160.0)
Inventory	(46.2)	(88.6)
Accrued expenses and other current liabilities	(684.2)	(136.7)
Income tax assets and liabilities	(195.1)	276.8
Other changes in operating assets and liabilities, net	(34.3)	(36.9)
Net cash flows provided by operating activities	235.2	1,015.8
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities	1,884.3	1,181.1
Purchases of marketable securities	(1,256.7)	(1,914.4)
Contingent consideration related to Fumapharm AG acquisition	300.0	300.0
Purchases of property, plant and equipment	(210.0)	(126.9)
Acquisitions of intangible assets	(855.2)	(28.6)
Other	(6.6)	(14.4)
Net cash flows used in investing activities	(744.2)	(1,203.2)
Cash flows from financing activities:
Purchases of treasury stock	(583.6)	0.0
Payments related to issuance of stock for share-based compensation arrangements, net	(25.5)	(29.6)
Net cash contribution to Bioverativ	302.7	0.0
Other	10.4	24.6
Net cash flows used in financing activities	(901.4)	(5.0)
Net decrease in cash and cash equivalents	(1,410.4)	(192.4)
Effect of exchange rate changes on cash and cash equivalents	7.9	15.1
Cash and cash equivalents, beginning of the period	2,326.5	1,308.0
Cash and cash equivalents, end of the period	$ 924.0	$ 1,130.7